指南与共识心脑血管急症创伤与烧伤重症综合管理与镇静镇痛

孤立性创伤性脑损伤患者抗血栓药物管理:跨学会共识文件

Management of Antithrombotic Drugs in Patients with Isolated Traumatic Brain Injury: An Intersociety Consensus Document.
指南 / 共识 · Neurocrit Care · 2023-04-07
一句话结论跨学会共识用德尔菲法提出28条声明,对孤立性创伤性脑损伤患者抗血小板药、维生素K拮抗剂和直接口服抗凝药的停用给出推荐,20条达成一致,但需大队列验证。

该共识由意大利神经外科学会神经创伤学分会、意大利止血与血栓研究学会、意大利麻醉镇痛复苏与重症监护学会、欧洲神经外科学会协会共同支持,工作组采用德尔菲法完成两轮问卷,在问卷前建立血栓和出血风险表(分高风险与低风险),将急性/慢性硬膜下血肿、硬膜外血肿、脑挫裂伤(脑内出血)、创伤性蛛网膜下腔出血等孤立性创伤性脑损伤场景与正在接受抗血栓治疗的患者匹配,涵盖抗血栓一级预防、心脏瓣膜假体、血管支架、静脉血栓栓塞症和心房颤动等登记适应证。结果提出28条声明,覆盖钝性孤立性创伤性脑损伤患者停用抗血小板药、维生素K拮抗剂和直接口服抗凝药的最常见临床场景;对7项推荐干预的适宜性等级投票,28个问题中20个(71%)达成一致,11个(39%)评为适宜、9个(32%)评为不适宜、8个(28%)适宜性不确定。结论认为初步建立血栓和/或出血风险评分系统可为有效管理提供理论依据,所列推荐可纳入本地流程,需大队列验证。

要点

  • 工作组提出28条声明,覆盖钝性孤立性创伤性脑损伤患者停用抗血小板药、维生素K拮抗剂和直接口服抗凝药的常见场景。
  • 28个问题中20个(71%)达成一致:11个(39%)评为适宜,9个(32%)评为不适宜,8个(28%)适宜性不确定。
  • 问卷前建立血栓和出血风险表,分高风险和低风险,将硬膜下血肿、硬膜外血肿、脑挫裂伤、创伤性蛛网膜下腔出血等场景与活动性抗血栓治疗匹配。
  • 抗血栓适应证涵盖一级预防、心脏瓣膜假体、血管支架、静脉血栓栓塞症和心房颤动。
  • 共识结论认为风险评分系统可提供理论依据,推荐可纳入本地流程,需大队列验证。

适用人群与场景

  • 钝性孤立性创伤性脑损伤且正在接受抗血栓治疗的患者,场景包括急性硬膜下血肿、慢性硬膜下血肿、硬膜外血肿、脑挫裂伤(脑内出血)和创伤性蛛网膜下腔出血。
  • 抗血栓治疗适应证包括抗血栓一级预防、心脏瓣膜假体、血管支架、静脉血栓栓塞症和心房颤动。

诊断标准与关键阈值

  • 问卷前建立血栓和出血风险表,将风险二分为高风险和低风险,通过匹配不同孤立性创伤性脑损伤场景与患者活动性抗血栓治疗计算风险。
  • 对推荐干预的适宜性投票分为适宜、不适宜和不确定;28个问题中11个(39%)评为适宜,9个(32%)评为不适宜,8个(28%)不确定。

研究设计与关键结果

  • 制定机构为意大利神经外科学会神经创伤学分会、意大利止血与血栓研究学会、意大利麻醉镇痛复苏与重症监护学会和欧洲神经外科学会协会;工作组采用德尔菲法完成两轮问卷,在多学科环境下进行。
  • 工作组提出28条声明,涵盖钝性孤立性创伤性脑损伤患者停用抗血小板药、维生素K拮抗剂和直接口服抗凝药的最常见临床场景,并对7项推荐干预的适宜性等级投票。
  • 28个问题中20个(71%)达成一致,11个(39%)评为适宜,9个(32%)评为不适宜,8个(28%)适宜性不确定。

证据类型、等级与局限

  • 证据类型:跨学会共识文件,采用德尔菲法两轮问卷和多学科工作组。
  • 局限:现有证据主要基于专家意见,缺乏高质量循证医学证据;停用和恢复抗血栓治疗目前经验性、变异大且依赖主治医师个体评估;需大队列验证。

对床旁实践的改变

  • 共识提出的风险评分系统和推荐可纳入本地流程,以形成更同质化的管理策略;作者认为初步建立血栓和/或出血风险评分系统可为有效管理提供理论依据。
  • 推荐需在大规模患者队列中验证。

指南或共识出处

  • 跨学会共识文件:孤立性创伤性脑损伤患者抗血栓药物管理,由意大利神经外科学会神经创伤学分会、意大利止血与血栓研究学会、意大利麻醉镇痛复苏与重症监护学会和欧洲神经外科学会协会支持。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: All available recommendations about the management of antithrombotic therapies (ATs) in patients who experienced traumatic brain injury (TBI) are mainly based on expert opinion because of the lack of strength in the available evidence-based medicine. Currently, the withdrawal and the resumption of AT in these patients is empirical, widely variable, and based on the individual assessment of the attending physician. The main difficulty is to balance the thrombotic and hemorrhagic risks to improve patient outcome.

METHODS: Under the endorsement of the Neurotraumatology Section of Italian Society of Neurosurgery, the Italian Society for the Study about Haemostasis and Thrombosis, the Italian Society of Anaesthesia, Analgesia, Resuscitation, and Intensive Care, and the European Association of Neurosurgical Societies, a working group (WG) of clinicians completed two rounds of questionnaires, using the Delphi method, in a multidisciplinary setting. A table for thrombotic and bleeding risk, with a dichotomization in high risk and low risk, was established before questionnaire administration. In this table, the risk is calculated by matching different isolated TBI (iTBI) scenarios such as acute and chronic subdural hematomas, extradural hematoma, brain contusion (intracerebral hemorrhage), and traumatic subarachnoid hemorrhage with patients under active AT treatment. The registered indication could include AT primary prevention, cardiac valve prosthesis, vascular stents, venous thromboembolism, and atrial fibrillation.

RESULTS: The WG proposed a total of 28 statements encompassing the most common clinical scenarios about the withdrawal of antiplatelets, vitamin K antagonists, and direct oral anticoagulants in patients who experienced blunt iTBI. The WG voted on the grade of appropriateness of seven recommended interventions. Overall, the panel reached an agreement for 20 of 28 (71%) questions, deeming 11 of 28 (39%) as appropriate and 9 of 28 (32%) as inappropriate interventions. The appropriateness of intervention was rated as uncertain for 8 of 28 (28%) questions.

CONCLUSIONS: The initial establishment of a thrombotic and/or bleeding risk scoring system can provide a vital theoretical basis for the evaluation of effective management in individuals under AT who sustained an iTBI. The listed recommendations can be implemented into local protocols for a more homogeneous strategy. Validation using large cohorts of patients needs to be developed. This is the first part of a project to update the management of AT in patients with iTBI.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Iaccarino C, Carretta A, Demetriades AK, et al. Management of Antithrombotic Drugs in Patients with Isolated Traumatic Brain Injury: An Intersociety Consensus Document. Neurocrit Care. 2023. PMID: 37029314. doi:10.1007/s12028-023-01715-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。